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ABSTRACT
Bioassay programs are integral in a radiation safety program. They are used as a method of
determining whether individuals working with radioactive material have been exposed and have
received a resulting dose. For radionuclides that are not found in nature, determining an exposure
is straightforward. However, for a naturally occurring radionuclide like uranium, it is not as
straightforward to determine whether a dose is the result of an occupational exposure. The
purpose of this project is to address this issue within the University of Nevada, Las Vegas’s
(UNLV) bioassay program. This project consisted of two compartments that studied the
effectiveness of a bioassay program in determining the dose for an acute inhalation of uranium.
The first component of the plan addresses the creation of excretion curves, utilizing MATLAB
that would allow UNLV to be able to determine at what time an inhalation dose can be attributed
to. The excretion curves were based on the ICRP 30 lung model, as well as the Annual Limit
Intake (ALI) values located in the Nuclear Regulatory Commission’s 10CFR20 which is based
on ICRP 30 (International Commission on Radiological Protection). The excretion curves would
allow UNLV to be able to conduct in-house investigations of inhalation doses without solely
depending on outside investigations and sources. The second component of the project focused
on the creation of a risk based bioassay program to be utilized by UNLV that would take into
account bioassay frequency that depended on the individual. Determining the risk based bioassay
program required the use of baseline variance in order to minimize the investigation of false
positives among those individuals who undergo bioassays for uranium work. The proposed
program was compared against an evaluation limit of 10 mrem per quarter, an investigational
limit of 125 mrem per quarter, and the federal/state requirement of 1.25 rem per quarter. It was
determined that a bioassay program whose bioassay frequency varies per person, depending on
iii

the chemical class of material being worked with, in conjunction with continuous air monitoring
can sufficiently meet ALARA standards.
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1.0 INTRODUCTION
Bioassays are a very necessary and important aspect of any radiological program in order
to ensure that those individuals who are working with radioactive materials are not being
exposed to excessive amounts of radiation. Currently at the University of Nevada, Las Vegas
(UNLV), bioassays are a fixed radiation protection measure for those individuals with access to
radiation laboratories where significant quantities of unsealed material can be used, referred to as
“level 3 or level 4 laboratories” in the UNLV Radiation Safety Manual, regardless of the activity
of the material being used by the individual worker. Initial bioassays are conducted when an
individual’s project and radionuclide being used for the project is determined so that a baseline
for the individual can be determined. Under the current bioassay program at UNLV, after the
initial bioassay individuals receive bioassays on a quarterly basis. This bioassay schedule does
not take into account the amount of activity being worked with, scope of work, radionuclide, or
the frequency that the individual does laboratory work involving the radioactive material.
Urine bioassays are currently conducted on a quarterly basis for thirty-five individuals in
the Radiochemistry program. Of these thirty-five individuals, twenty individuals are tested for
potential uranium exposure due to occupational practices. Interpreting the data from these
individuals’ bioassays requires a different approach than other radionuclides. Radionuclides,
such as plutonium and technetium, are not found in nature, therefore if they are found in the
body a safe determination can be made that the exposure is the result from an occupational
exposure. However, uranium is a naturally occurring nuclide, and therefore it can be found
present in an individual’s body who has never had an occupational exposure. This makes it more
difficult when testing workers to determine if the uranium found in a sample can be attributed to
an occupational exposure or an environmental exposure. It is necessary when conducing
1

bioassays to determine at which point above the natural occurrence of uranium is due to an
occupational exposure.
The samples are sent to an outside certified laboratory, currently UNLV uses
TestAmerica, where it costs $150 to test each isotope. Alpha spectrometry is used to measure the
sample for uranium isotopes: uranium-238, uranium-235, and uranium-234. It is assumed that
any intake of uranium-233 is included in the final uranium-234 analysis. This is because the
isotopes energies are very close and the alpha spectrometer is unable to identify each isotope’s
energy separately. Most uranium sample results are above the minimum detectable limit (MDL),
which is 1.5E-2 dpm per sample, but are within the acceptable range of 0.05 – 0.5 microgram per
day as defined for Reference man in ICRP 23. The results seen are attributed to natural
environmental exposure and potential occupational exposure.
However, these bioassays are very expensive for the radiological safety program at
UNLV to conduct on a quarterly basis. With each bioassay costing $150 for thirty-five people,
that’s a minimum of $5,250 per quarter and $21,000 per year. This figure does not take into
account any additional testing that may be required to investigate an abnormal bioassay result or
hiring consultants to evaluate potential positive results. Further investigating potentially positive
bioassay results can result in an additional of tens of thousands of dollars per incident. From the
aforementioned total, the question becomes, “Is it possible to reduce the amount of money spent
on these bioassays while still applying ALARA standards?”
1.1 Research Objectives
It may be possible to reduce the amount of money spent on urine bioassays by developing
a risk-based bioassay program for UNLV, as well as continuing to employ ALARA (As Low As
Reasonably Achievable) techniques. This risk based program will account for investigation and
2

action limits to be set that determine the frequency of bioassays necessary to protect those
individuals working with uranium in UNLV’s laboratories. This program will also evaluate the
use of additional monitoring techniques, such personal air monitoring, to be used with bioassay
to ensure workers are not being exposed to doses exceeding the set occupational limits.
Investigation levels will take into account activity levels, frequency of radioisotope usage, the
radioisotope being used, chemical form of radioisotope, and how the radioisotope is being used.
By setting risk-based guidelines it would be possible to more accurately determine the number of
bioassays necessary per person in a year, thus potentially saving money for the program.
Uranium will be the radionuclide of interest used in determining the possibility of
developing a risk-based bioassay program. Uranium will be used as the radionuclide of interest.
Due to uranium occurring in nature, it can exist in the body naturally. Therefore, it is important
to determine if the amount of uranium found in a worker’s body is as a result of the individual
being exposed to an occupational exposure or a part of natural body burden resulting from
environmental exposure. An additional factor that will be used in structuring the bioassay
program is focusing only on the potential exposure of uranium via an inhalation pathway. This
pathway was chosen because in a laboratory setting it is the exposure pathway that is most likely
to occur, therefore making it the largest concern. The scenario used will be if an individual had
an acute exposure where they inhaled a determined activity of uranium.
Frequency of urine analysis as an effective bioassay method can result in uncertainties
when determining if individuals have been exposed to uranium. The proposed research will focus
on correlating amounts of uranium in urine to time of inhalation and determining whether urine
analysis should be done more frequently dependent upon the amount of uranium work and also if
urine analysis alone is sufficient in determining exposure levels. The ICRP 30 model of the
3

Human Respiratory Tract will be the basis of the first part of the project. This is due to the fact
that it is the model that the Nuclear Regulatory Commission bases its ALI and DAC information
on. Once the ICRP 30 version of the Respiratory Tract is modeled and coded in MATLAB’s
Simulink, it will be benchmarked to ensure the values correlate to previously determined values.
Once benchmarked, the lung model will then be connected to ICRP 30’s Gastrointestinal Tract
Model and ICRP 30’s biokinetic model to create excretion cures for future use by UNLV. These
excretion curves will be created from the urine compartment in the model. These excretion
curves will determine the amount or uranium found in urine at specified days if the urinary
excretions were studied for one year.
The excretion curves based off ICRP 30 are being created because federal and Nevada
state regulations are based off ICRP 30 data. They have not been changed to reflect updated
information that has been presented in recent publications in ICRP 66, 100, and 68. These curves
are also experimental and the data created by them cannot be compared against previously
existing values to determine their accuracy.
The second part of the project includes utilizing the excretion curves based off ICRP 66’s
Human Thoracic Respiratory Model (HTRM) and dose coefficients from ICRP 68 to determine
what bioassay frequency allows for the investigation and evaluation limits to be met. The
excretion curves that have been accepted and published by Oak Ridge National Laboratory will
be used to estimate the amount of uranium that was inhaled at time = 0 based on the
concentration detected via urine bioassay. These values will then be calculated by a monthly,
quarterly, semi-annual, and annual basis to determine the dose at each time interval. The doses
calculated will then be compared to the evaluation and investigation limits to determine potential
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bioassay frequencies. For those doses that require a bioassay frequency of less than a month,
additional air monitoring will be considered.

5

2.0 BACKGROUND
2.1 Uranium
Uranium is a silvery-white metal that occurs naturally as the isotopes Uranium-234,
Uranium-235, and Uranium-238. These isotopes of uranium are long living alpha emitters whose
energies are between 4.15 and 4.8 MeV. Uranium’s uses include nuclear reactor fuel (to generate
electricity), radioisotope production, propulsion steam, and research [7]. Although heavy water
reactors are able to operate on natural uranium composition, most nuclear reactor fuel require for
the enrichment of isotope Uranium-235. Because of its small abundance in nature Table 1
(0.72%), Uranium-235 must be enriched through a process of gaseous diffusion, centrifugation,
or laser separation. This enriched isotope then undergoes bombardment of thermal neutrons that
results in fissioning and a large amount of energy is released. By enriching the amount of
Uranium-235, its concentration increases which in turn allows for a smaller reactor size and
quality of fuel.
Table 1: Isotopic Abundance in natural uranium [7]

Isotope

Natural

Typical
Commercial
Feed
Enrichment

Uranium-238

99.28

97.01

99.80

Uranium-235

0.72

2.96

0.20

Uranium-234

0.0055

0.03

0.0007

Depleted

As stated before, enriching uranium allows for the concentration of Uranium-235 to be
increased to at least 3%. The percentage of enrichment varies for the particular type of fuel being
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created [7]. It should be noted that during the enrichment process the amount of Uranium-234
also increases and causes the enriched uranium to have a higher activity. From enriched uranium,
depleted uranium is created as a byproduct. Depleted uranium, in comparison to enriched
uranium, has a lower concentration of Uranium-234 and 235, a lower activity, and higher
density. Depleted uranium can be used as counterweights, target elements in Department of
Energy Plutonium production reactors, research projects, etc.
2.2 UNLV Bioassay Program
The Bioassay Program at the University of Nevada, Las Vegas (UNLV) is a requirement
of the Radiation Safety Program and is managed by the Risk Management and Safety
Department at UNLV [15]. The program arose from an incident at UNLV on October 1, 2011
[14]. A urine bioassay sample was reported to have an activity that was above the detection limit
for uranium, specifically uranium-238, uranium-235, and uranium-234. Due to uncertainties and
unknowns related to the cause of the potential significant dose, it was not possible to determine if
the exposure was because of an occupational exposure. For the individual in question the
following measures were taken: performance of additional urine bioassays, fecal samples, a chest
count, thorough review of work history, the hiring of an outside consultant, and suspension from
all lab work [14]. From the investigation it was determined that due to lab work conducted in a
glove box the individual may have inhaled a mixture of uranium-238 and uranium-233. The
activity was performed two times in the time span of six months. At the end of the investigation
it was concluded, that the inhalation exposures did not cause a significant exposure and the
“false” positive was a result of environmental causes [14]. The individual was from an area in
Nevada that had a high natural uranium background and their body naturally had high uranium
levels.
7

Because of the incident, it was determined that UNLV did not have an adequate bioassay
program. The state of Nevada required UNLV to implement a bioassay program that required
additional surveillance of individuals working with radionuclides. This additional surveillance
included instituting a mandatory quarterly bioassay for workers in the radiochemistry program.
The additional surveillance was not due to a high potential exposure, but was intended to solve
the problem of poor record keeping at UNLV.
UNLV currently employs the Radiation Safety Office (RSO) to ensure that the university
remains in compliance with the University’s licenses, which are a Broad Scope Type A
Radioactive Materials License No. 03-13-0305-01gRA and a Service License No. 03-13-0305-02
[15]. These licenses are granted by the state of Nevada to UNLV allows for the Radiation Safety
Office to develop, direct, and oversee operation of the university’s radiation safety program. In
implementing the program, the Radiation Safety Committee and the Radiation Safety Officer are
committed to maintain that doses to the public and workers are kept at ALARA. This is done by
being responsible for personnel monitoring and dosimetry services, training, radioactive waste
management, consultation for laboratory design (including shielding and any matters related to
radiation science or safety [15]. The Radiation Safety Office maintains the authority to stop any
operation that includes the use of radioactive material that may affect an individual’s health and
safety, not in compliance with procedures outlined in the Radiation Safety Manuel, NAC 459, or
UNLV’s radioactive material license’s requirements.
Nevada Administrative Code 459, or NAC 459, provides all regulations related to
hazardous materials [15]. All policies created and enforced by the Radiation Safety Office are
based off this state regulation. This is because Nevada is one of thirty-seven agreement states in
the United States. As an agreement state, Nevada has entered and signed an agreement with the
8

Nuclear Regulatory Commission (NRC) which authorizes the state to regulate uses of radioactive
materials within the state.
The policy for the University of Nevada, Las Vegas and the NRC is to maintain radiation
exposure levels at ALARA, As Low As Reasonably Achievable [15]. Radiation exposure limits
for UNLV are set at 10% of the annual limit, which is 0.5 rem [15]. This limits means that plans
and precautions are made to ensure that work done at UNLV should not result in an annual dose
greater than the determined limit. Setting the limit at 0.5 rem also assists in ensuring that workers
do not exceed the absolute annual limit that has been determined by federal regulations to
potentially cause a biological effect. The annual limit is defined to be 5 rem by NAC 459.325
Table 2. The 10% of the annual limit standard does not include the general public or pregnant
workers. Policies are set in place to ensure that limits are not exceeded.
Table 2: Annual Limits for Exposure [15]
Annual Limits for Occupational Radiation Exposure
Total Effective Dose Equivalent

5000 mrem (0.05 Sv)

Any Organ Except Lens of Eye

50000 mrem (0.5 Sv)

Skin and Extremities
(Shallow Dose Equivalent)
Lens of Eye
(Lens Dose Equivalent)

50000 mrem (0.50 Sv)
15000 mrem (0.15 Sv)
500 mrem (0.005 Sv)
duration of pregnancy

Declared Pregnant Worker

The current general principle in UNLV’s internal dosimetry policy is that bioassays are
required after any incident where internal exposure due to deposited radioisotopes is a possibility
[15]. These bioassays can include testing blood, urine, fecal samples, or nose swabs. Urine and
fecal bioassay samples are analyzed by an independent certified laboratory to determine
9

exposure of internal radioactive materials. Once samples are collected, they must be stored in
laboratory issued containers. Samples must then be preserved, packaged, and shipped per the
laboratory’s instructions.
In the event of an emergency, there are specific bioassay procedures that have been
outlined [15]. Immediate evaluation and decontamination of the individual is required once an
incident occurs where radioactive material may have been inhaled, ingested, or absorbed. If
during the personal survey contamination is found on the face, nose, or mouth then face smears
and nasal swabs must be taken. Documentation of the data must be taken in order to ensure that a
correct analysis can be made. The documentation should contain the following information: time
contamination event occurred, date of contamination event, what events led to emergency, initial
and current survey results, and initial contamination levels, radiation dose, and chemical
exposure. During urinalysis it is important to collect the required urine volume, record the
individual’s name, and provide all information when sending urine sample to laboratory for
analysis. For further documentation it is important that the analysis results, calculated committed
dose equivalent, and total effective dose equivalent are all in the worker’s exposure file.
Uranium bioassays are currently conducted on a quarterly basis, where 24 hour urine
collection is used as the sample volume [15]. Those individuals whose samples’ results are
higher than 125 mrem undergo further investigations. This investigation includes more bioassay
samples, total body counts, and determining when the potential exposure occurred.
2.3 ICRP 30 Respiratory System Model
When discussing uranium intake, the primary routes of concern are inhalation and
ingestion. The inhalation route of uranium is described through the Respiratory Tract Model. The
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Respiratory System Model’s purpose is to address the behavior of materials once they enter the
body via inhalation. This behavior includes distribution, retention, and excreted from the body.
The Respiratory System Model was first introduced by the International Commission on
Radiological Protection (ICRP) in 1979 with Publication 30 [4]. It is a dosimetric model that
relates how a radioactive aerosol enters the body via inhalation. After inhalation, the dose that
regions within the respiratory system and other organs and tissues in the body receive vary
because of how distribution of material occurs in the lung. Distribution and retention estimates of
material is based off a model proposed in a report by the ICRP Task Group on Lung Dynamics
created in 1966 [4]. The Respiratory System Model from ICRP 30 accounts for particle size,
defining three retention class based on chemical form, and elimination routes from the lung.
In the ICRP 30 model, the respiratory system is divided into three regions: nasal passage
(NP), trachea and bronchial tree (TB), and the pulmonary parenchyma (P)[4]. The model also
includes the Lymph Nodes as an elimination pathway, where materials in the Lymph Nodes are
assumed to either reside indefinitely or be transferred to body fluids depending on the
compartment the materials are located in. To understand the pattern of distribution of particulates
in the lung, the model assumes that the aerosols had an activity median aerodynamic diameter
(AMAD) equal to 1 µm. The fraction of inhaled material that is initially deposited into each
region is described by the following parameters: DN-P = 0.30, DT-B = 0.08, and DP = 0.25 [4]. It is
assumed in the model that the dose received in the nasopharyngeal region is negligible because
for most particle sizes the dose received in the nasopharyngeal region is significantly smaller
than the doses received by other regions [4].

11

Figure 1: ICRP Respiratory tract model [4]
The respiratory system model, shown in Fig. 1, is separated according to the three
aforementioned regions and the clearance pathways that occur in the respiratory system for each
of these regions. The clearance pathways include: absorption processes and particle transport
processes [4]. Compartments A, C, and E on the left-side of the model are involved in the
absorption process; material in these compartments clear to the body fluids. Compartments in B,
D, F, and G on the right-side of the model are associated with particle transport processes, such
as mucociliary transport. These processes allow for materials to translocate to the gastrointestinal
tract. Within compartments H, I, and J multiple processes occur, though its overall goal is to
remove dust from the lungs. Material in compartment H transfers to compartments I and J where
they either continue through compartment I to the body fluids or are retained indefinitely in
compartment J. In Table 3 Associated with each compartment are clearance half-times (T) and
fractions (F) of material leaving at specific rates.
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Radionuclides are categorized according to chemical forms that are determined by the
radionuclide’s metabolic data [4]. With information on the chemical form, it is possible to
determine the classification of D, W, and Y. Table 3 provides information regarding the three
solubility classes: Class D, Class W, and Class Y. Class D (days) materials have a clearance halftime less than ten days. Class W (weeks) materials clearance half-time lasts between 10-100
days, whereas Class Y (years) materials clearance time is greater than 100 days. These categories
relate clearance half-times with solubility class, so that it can be determined how long a material
will be retained in each region of the lung.
Table 3: ICRP 30 Solubility Classes [4]

Region
N-P
T-B
P

L

Compartment
A
B
C
D
E
F
G
H
I
J

D
T (day)
0.01
0.01
0.01
0.2
0.5
N.A
N.A
0.5
0.5
N.A.

F
0.5
0.5
0.95
0.05
0.8
N.A
N.A
0.2
1
N.A.

CLASS
W
T (day)
F
0.01
0.1
0.4
0.9
0.01
0.5
0.2
0.5
50
0.15
1
0.4
50
0.4
50
0.05
50
1
N.A.
N.A.

Y
T (day)
0.01
0.4
0.01
0.2
500
1
500
500
1000
∞

F
0.01
0.99
0.01
0.99
0.05
0.4
0.4
0.15
0.9
0.1

2.4 ICRP 66: Human Respiratory Tract Model
The Respiratory Tract Model was modified and updated in 1994 to the Human
Respiratory Tract Model (HRTM) [16]. This publication provided values, biokinetics, transport
rate constants, and a model to better help understand how radionuclides travel through the
respiratory system. In Fig. 2 the Human Respiratory Tract Model is divided into compartments
and paths that detail how deposited radionuclides are cleared from the body once inhaled [16]. In
13

this model particle transport competes with particle dissolution, which affects the rate of
absorption of particles into blood. Absorption to blood occurs in most parts of the HRTM except
for the first part of the extrathoracic compartment (ET1). It is assumed that an activity can be
absorbed resulting from material located in the alimentary tract that resulted from the coughing
of material from lungs and consequently swallowed [16]. The total activity level excreted via
urine is determined by the amount of activity absorbed to the blood from the respiratory and
alimentary tracts.

Figure 2: ICRP Respiratory Tract Model [16]
The respiratory system is divided into two compartments, the extrathoracic (ET) and
thoracic tissues [16]. The extrathoracic region is divided into the anterior nasal passage and the
posterior nasal passage. The anterior nasal passage accounts for the removal of particles and
deposits through blowing of the nose. Whereas, the posterior nasal passage includes incidents
where inhaled radionuclides were swallowed or absorbed into the blood. The posterior nasal
passage is composed of the nasopharynx, oropharynx, and larynx; the larynx is further separated
into the bronchi (BB), bronchioles (bb), and alveolar interstitium (AI). From the thoracic
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compartment particles are transferred to the blood through absorption, the gastrointestinal
(alimentary) tract through mechanical processes, and through the lymphatic channels for the
lymph nodes (LN) Fig 3 [16].

Figure 3: Clearance Routes from Respiratory Tract [16]
Dissolution is also a phenomenon that needs to be considered when discussing the
chemical and physical forms of the radionuclide in question for an inhalation dose. The rate of
dissolution is dependent upon the radionuclide’s physical and chemical form [16]. In the HRTM,
there are two assumed pathways: dissolved activity can bind to respiratory tract tissues and
activity dissolved in the respiratory system is absorbed immediately to the bloodstream [16].
This absorption is then assumed to occur at the same rate in all regions within the model (with
the extrathoracic (ET1) compartment being an exception since no absorption occurs). This
absorption rate decreases with time due to values for the relatively soluble, moderately soluble,
and relatively insoluble aerosols.
The solubility classes published in ICRP 30 were updated in ICRP 66 to account for how
different chemical forms would transfer and be retained in the lung. The solubility classes D, W,
and Y names were changed to absorption types F, M, and S [16] to describe the correlation
between solubility, dissolution rate, and absorption level. Type F relates to a relatively soluble
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material that would undergo a fast dissolution and high absorption level to the bloodstream. Type
M is a moderately soluble material with a moderate dissolution rate and an intermediate
absorption level to the bloodstream. Type S is a material that is relatively insoluble with a slow
dissolution rate and low absorption level to the blood.
Each absorption type has dissolution parameters related to them that can be applied to
each respiratory compartment, except ET1 [16]. These parameters include fr , sr, and ss. fr is the
fraction of deposited material, and sr, and ss are the dissolution rates (rapid and slow
respectively). In Table 4, Type F has a fr = 1.0, meaning that there is no slow dissolution rate;
the remaining two types do have fr < 1.0 which is indicative of those materials experiencing
some slow dissolution rates [16].
Table 4: ICRP 66 Absorption Types [16]
Material

fr

sr (d-1)

ss (d-1)

Type F

1.0

100

-

Type M

0.1

100

0.005

Type S

0.001

100

0.0001

Figure 4 shows how the aforementioned parameter are useful in determining materialspecific dissolution rates. The figure correlates dissolution rate with time and assumes that the
dissolution rate decreases with time [16]. From the figure it is also assumed that a fraction of
deposited material (fr) dissolves at a fast rate (sr). The remaining fraction (1- fr ) dissolves at a
slower rate (ss ).
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Figure 4: Time dependent absorption within the HRTM [16]
2.5 CDC Fourth National Report on Human Exposure to Environmental Chemicals
The Fourth National Report on Human Exposure to Environmental Chemicals published
by the Centers for Disease Control and Prevention is an assessment of determining
environmental chemicals the United States population has been exposed to [11]. The purpose of
the report is to prevent environmental chemical exposure by establishing reference values that
can be used to determine whether a group or person has been exposed. This assessment was done
via the use of biomonitoring. Biomonitoring determines chemical exposure by measuring blood
or urine for chemicals or metabolites. The amount of a chemical present in the body from
ingestion, inhalation, and absorption is reflected in blood, serum, and urine levels. Although a
measurement of an environmental chemical in blood, serum, or urine is indicative of exposure, it
is not definitive in determining if the exposure can result in disease or other effect [11].
The report provides geometric means and percentiles of environmental chemicals for age
groups, genders, and race/ethnicity based on blood, serum, and urine levels. The geometric mean
provided a better estimate for data that are distributed with a long tail at the upper end of the
distribution [11]. It is less influenced by high values than the arithmetic mean. This weighted
mean was calculated with a 95% confidence interval. Also, to provide additional information
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about the shape of distribution, the 50th, 75th, 90th, and 95th percentiles were provided. The urine
concentrations used in the geometric mean and percentiles are measured in µg/L. For uranium, it
is important to note that the report provides information for urinary uranium and urinary uranium
(creatinine corrected). For calculations done in the project, the values for urinary uranium were
used because the creatinine accounts for urine dilution that may result from increased fluid use,
lean body mass, or renal function.
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Figure 5: Urinary Uranium Geometric mean and selected percentiles of urine
concentration (in µg/L) for the U.S. population [11]

2.6 Dosimetry Principles
In order to determine the dose to a tissue, the committed dose equivalent (CDE), H50,
must be calculated (Eq. 1). The equation shows that H50 is the total dose equivalent calculated
for a specific organ or tissue after an intake of radioactive material [4]. When calculating dose to
tissues and the body, the assumption is generally made for a time period of 50 years. This 50
year assumption is based on the average working life-time for an adult.
H50 (T←S) = 1.6 ∙ 10-10 [ US Σ SEE (T←S)]
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Sv

(1)

US is the number of transformations that is calculated in the target organ or tissue over 50
years after intake of radioactive material [4]. SEE (T←S) is the specific effective energy which
is the energy imparted per gram of target tissue from a source tissue. 1.6 ∙ 10-10 is a constant
describing the number of joules in 1 MeV, 1.6 ∙ 10-13, and the conversion of g-1 to kg-1, 103 [4].
The specific effective energy (SEE) is a variable that takes into account the contribution
of each radionuclide emitted. Eq. 2 describes how the SEE value is calculated.
SEE (T←S) = ∑

𝑌𝐸𝐴𝐹(𝑇←𝑆)𝑄
𝑀

MeV g -1 per transformation (2)

Where, Y is the yield of radiation type per transformation of radionuclide, E is the
average or unique energy of radiation (MeV), and AF (T←S) is the absorbed fraction of energy
in target organ [4]. The absorbed fraction values can be found in ICRP 23 Appendix I for each
target and source tissue for photon energy [5]. Q is the quality factor for a radiation type. For
alpha particles the quality factor is 20, for Beta/Gamma rays/X-rays the quality factor is 1, and
for Neutron/Protons the quality factor is 10 [4]. M is the defined mass of the target organ in
grams, g.
Once the committed dose equivalent is calculated, it is used to calculate the effective
dose in Eq. 3. The weighting factor, WT, is determined from Table 5.
H E,50 = ΣT wT HT
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(3)

Table 5: Weighting Factors Recommended for Stochastic Effects [4]
Organ/Tissue

wT

Gonads

0.25

Breast

0.15

Red Bone Marrow

0.12

Lung

0.12

Thyroid

0.03

Bone Surfaces

0.03

Remainder

0.30
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3.0 DEVELOPMENT OF ICRP-30 URINE EXCRETION CURVES
The methodology used to determine the possibility of developing a risk-based bioassay
program for uranium usage in laboratories was composed of two main components. The first
component comprised of developing a MATLAB Simulink model of the ICRP 30 Respiratory
Tract model that can be used by the UNLV Radiation Safety Officer to create uranium excretion
curves to investigate bioassay cases in house. Because the State of Nevada uses ICRP 30 as the
basis for its regulations, it was necessary to utilize ICRP 30 methodology to create a model for
uranium. In this project, a previously modeled MATLAB version of ICRP 30’s biokinetic model
and Gastrointestinal Tract model [2] was expanded to include the ICRP 30 lung model. This
model also includes an integration model that allows for the concentration of uranium in urine to
be determined from the biokinetic models.
3.1 MATLAB and Simulink
MATLAB is a software that is used by engineers and scientists to create and analyze
systems [3]. In MATLAB, coding and the usage of built-in functions and graphics can be used
together to create models meant for experimentation. For this project the student version,
MATLAB R2015b, was used to create models simulating the respiratory tract.
The Simulink suite was purchased as an add-on to the MATLAB R2015b version.
Simulink is a suite that allows for multidomain simulation by providing a block diagram
environment and, therefore was thought to be the best method of modeling radionuclide
transportation [3]. It allows for model-based designs to be simulated and continuous
testing/verification of systems to occur while generating code automatically. In order to create
the models for ICRP 30’s Respiratory Tract, blocks were used that were provided by the
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software in its customizable block library. These blocks allowed for solvers necessary for
modeling and dynamic system simulation.
3.2 Model Development in MATLAB Simulink
Simulink allows for the distribution and retention of radionuclides to be modeled through
a set of differential equations in order to determine the resulting dose. Previous research done by
Hrycushko provided the basis for how compartments could be set up and modeled in Simulink
[1].The ICRP 30 respiratory tract compartment D model created by Hrycushko was selected as a
template for developing the entire ICRP 30 respiratory tract model. ICRP 30 was modeled in
Simulink because it is the basis for NRC Guidelines and it is still used as the basis for regulations
for UNLV and Federal entities. Compartments of the ICRP 30 Respiratory System were modeled
to depict the inhalation, distribution, and retention of a radionuclide and then later connected
with ICRP 30 Gastrointestinal Tract and Biokinetic models to determine resulting activity found
in urine [2].
Eq. 4 is an example of the first order differential that was modeled via Simulink. This
equation is specific to Compartment A in the ICRP 30 Respiratory System Model [4]. This
describes how material is cleared from the compartment and how activity is derived in
Compartment A at time t. Each compartment of the Respiratory System Model has a specific
differential equation that is similar to Eq. 4 that takes into account how a radionuclide is handled
specifically for each compartment.
𝑑
𝑑𝑡

qa(t) = I(t) ∙ DN-P ∙ Fa – λaqa(t) – λRqa(t)

Where:
I(t) is the initial amount inhaled
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(4)

D is the fraction of the initial inhaled amount that is deposited in a region of the lung
F is the defined fraction of material entering a compartment
λa-i is the biological clearance rate specific to each compartment
λR is the radioactive decay constant for the radionuclide in question
Eq. 5 was used to calculate the biological clearance rate (λa-I) and Eq. 6 was used to
calculate the radiological decay constant (λR) [4]. Eq. 5 was provided in ICRP 30 as the method
of determining the biological clearance rate. For both variables, time was converted from days to
seconds. This was done because MATLAB Simulink time runs in seconds and the activity unit
used in calculations in the model was in Bq (decays per second).

λ=

0.693
86400T

(5)

Where:
𝜆 = Biological Clearance Rate (s-1)
T = Removal half-time (days)

λ =

ln2
T1/2

(6)

Where:
T1/2 = half-life of the radioisotope (units in seconds for calculations)
Fig. 6 depicts how intake and distribution is handled in Compartment A of the ICRP 30
Respiratory System in MATLAB Simulink.
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Figure 6: Compartment A Simulink Model
In calculating the dose conversion coefficient and urine content, an acute inhalation of 1
Bq at time = 0 was used. A step block was used to depict the initial inhalation. For ICRP 30, the
assumed AMAD particle size is 1µm. The particle size changes later to 5 µm in ICRP 66 with
the updated Human Respiratory Tract Model. This initial activity was then divided amongst the
compartments in the model. The fraction used for each compartment was based on the assigned
fraction values outlined in Table 3 detailing the ICRP 30 Solubility Classes. Once activity was
derived in each compartment through modeling the aforementioned differential equations, a
variable step ODE solver was used in the Simulink model to integrate the activity for 50 years.
This solver determined the total number of transformations (Us) in each compartment that was
consequently used to calculate the dose from a radionuclide to the Respiratory System. Eq. 2
was modeled to solve for the specific effective energy (SEE) values, which was then used in
conjunction with the total number of transformations to calculate the committed equivalent dose.
The effective dose was then determined for the lung compartment by utilizing Eq. 3. This value
included the usage of tissue weighting factors provided in ICRP 26. Fig. 7 shows how the
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MATLAB Simulink model calculated the total number of transformations, specific effective
energy (SEE) values, and the committed equivalent dose for the lung compartment. The
Effective Dose equation was completed in Microsoft Excel.

Figure 7: Calculating Committed Equivalent Dose for Compartment A
3.3 Model Benchmarking
Benchmarking the model was necessary to ensure that the model was working correctly.
This benchmarking was done by running the model at time equals 50 years, in order to compare
US values, SEE values, and committed equivalent dose values to the literature values provided in
ICRP 30 for the lung [4]. The time 50 years is significant because that it is the pre-determined
working life acknowledged for an individual and is the defined time interval for committed dose.
The radionuclide that was chosen to build the initial lung model was Uranium-238 and Class Y
materials. Class Y materials were used because all solubility class values were available and it
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represents the material with the longest clearance time. The literature values for the US, SEE, and
committed equivalent dose that correspond to Uranium-238 were used as benchmarking values.
Tables 6 is the comparison between the values output by the Simulink model and the
ICRP 30 literature values for the Lung compartment for U-238 at time equals 50 years. The
values created by the Simulink model ranged from 1.37 to 4.44% different from the literature
value. This difference could be attributed to the fact that the daughters of U-238 were not
accounted for in the model’s calculations. The radiological half-life for the radionuclide of study
and chemical class of material can be changed within the model in order to study how lung dose
for various radionuclides can be calculated.
Table 6: Benchmarking Comparing Simulink Model Values to ICRP 30 Values
Simulink
Model

Literature
Value

Percent
Difference

Number of Transformations
(Transformations/Bq)

1.93E+07

1.90E+07

1.37

Specific Effective Energy
(MeV per g per Transformation)

8.37E-02

8.50E-02

1.48

Committed Dose Equivalent (Sv/Bq)

2.58E-04

2.70E-04

4.44

Effective Dose (Sv/Bq)

3.096E-05

3.20E-05

3.25

In Table 6, the lung compartment’s contribution to the effective dose was calculated by Eq. 3
where the weighting factor was defined as 0.12 for the lung.
3.4 Development of Excretion Curves
Once the values were benchmarked and deemed acceptable the lung model was then
connected to ICRP 30 Gastrointestinal Tract and Biokinetic models that were created in an
adjacent project [2]. The initial intake continued to be modeled as an acute inhalation of 1 Bq in
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the lung model. Because the Gastrointestinal Tract model had previously been used to determine
an ingestion dose, it was necessary to ensure that the initial activity in that particular model was
set to 0, so that the only activity seen would be due to the initial activity in the lung. Exports
from the lung model were also connected to the existing Gastrointestinal Tract and Body Fluids
compartments for a total activity to be calculated for the entire model.

Figure 8: Lung Model Subsystem
Figure 8 is an example of a subsystem that was used in the MATLAB Simulink model.
The Lung model compartment shown in the figure is a subsystem [3]. It is a basic representation
of the information that is inported and exported in the model. Inports can be information such as
constants or information that is taken from another subsystem. Exports can be information that is
connected to another subsystem, graphs, or displays that show the numerical value calculated in
the subsystem [3]. For the subsystem shown in the figure, the exports are a mixture of
information sent to other subsystems, Body Fluids and GI Tract, and numerical displays of
information calculated in the subsystem, SEE and Organ Dose.
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Figure 9: MATLAB Simulink Model Computing Total Urine Activity
Fig. 9 is a urine compartment was added to the model to calculate the total activity
derived from the Biokinetic Model. This urine compartment contains a “Simout” block that
allows for an input signal and writes the signal data created from the model to a MATLAB
workspace [3]. Once the data, uranium activity in urine per unit time, is exported to the
MATLAB workspace, it is used in a code that was created to determine the graphical integration
for any specific time period. For the purpose of the project the specified time periods were 30
days, 90 days, 180 days, and 360 days. Each graphical integration was ran for an entire 24 hours
because bioassay sample volumes are collected in 24 hour voids. The model ran for 370 days and
output the activity value that corresponded to the given time period. The model was run for 370
days to determine if the amount of uranium in urine changed after the 360 days (annual)
bioassay.
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The excretion occurs in two distinct phases, therefore there were two models created to
simulate and capture this excretion behavior of uranium into urine. The first excretion includes
the direct impulse of activity that stems from the body fluids released from the lung and the
Gastrointestinal Tract. The second excretion curve does not include this direct impulse because
the direct impulse is the dominant action shown in the resulting curve and does not depict how
activity is excreted via various other pathways. The models were separated so that the
contribution from each impulse could be observed and examined separately. Fig. 10 depicts the
behavior of the material when the direct impulse is not included in the excretion curve for Class
D materials. Fig. 11 depicts when the direct impulse from the Body Fluids is included in the
excretion curve for Class D materials. The top curve in Fig. 11 was the curve excreted in the
MATLAB workspace, whereas the bottom curve was a close up of the workspace curve provided
by a scope added to the subsystem in order to observe a more detailed view of the curve. The
direct impulse is the prominent action seen because it is greater than the activity amounts that
undergo the biokinetic model. The excretion curves for Class W and Y materials are located in
Appendix A. The difference in activity for each of these excretion curves is shown in Tables 7
and 8.
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Figure 10: Class D Material Excretion Curve (No Direct Impulse)
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Figure 11: Class D Material Excretion Curve (Including Direct Impulse)
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Table 7: Urine Activity (Bq) Values per 24-hr (Not Including Direct Impulse)
Class D

Class W

Class Y

Time
(day)

Activity
(Bq)

Activity
(Bq)

Activity
(Bq)

30
90
180
360

4.18E-07
4.34E-08
3.14E-09
5.32E-10

1.25E-07
4.08E-08
1.27E-08
1.41E-09

5.84E-09
2.46E-09
2.18E-09
2.096 E-9

Table 8: Urine Activity (Bq) Values per 24-hr (Including Direct Impulse)
Class D

Class W

Class Y

30

Activity
(Bq)
4.24E-07

Activity
(Bq)
1.48E-07

Activity
(Bq)
2.23E-08

90

4.63E-08

1.096E-07

1.82E-08

180

3.97E-09

1.17E-07

1.75E-08

360

6.007E-10

1.147E-07

1.91E-08

Time
(day)

The excretion curves displayed showed the activity excreted over one year and were
created for Uranium-238 for solubility class D, W, and Y. In the lung model, the T and F values
Table 3 had to be changed for each compartment in the lung model and the f1 Table 9 value was
changed in the small intestine model to account for solubility class differences. For
compartments where there was not a T and F value provided, the previous solubility class
information was used. Solubility Class Y was used for missing values in Class W and Class W
values was used for missing values in Class D. There was no method of benchmarking the
created excretion curves because there was not an excretion curve based on ICRP 30 found in
research.
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Table 9: f1 values for Inhalation Classes [4]
Inhalation
Class

f1

D

0.05

W

0.05

Y

0.002
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4.0 BIOASSAY PLAN DEVELOPMENT
Currently, bioassay results are studied to determine whether they are above the MDL.
Most samples do come back as being above the MDL, however they are in the range of the 0.05
µg to 0.5 µg per day for reference man. This method could result in the investigation of a high
number of false positives. A proposed bioassay plan must be able to see beyond the natural
expected change from a dose and whether a dose can be assigned without risking a dose to the
natural variance. To allot for this a proposed bioassay plan must take into account variance. The
minimum detectable activity provided that can be detected by the testing laboratory was
converted to mass for each uranium radionuclide in question. Variance was then calculated to
take into account the dose at which false positives should not be seen. Once the variance was
calculated and applied to each baseline group and uranium radionuclide, a dose was calculated
for specific time periods.
Once the variance is determined, the proposed bioassay plan will be compared to doses
to determine if they meet the federal requirement of 1.25 rem per quarter and the UNLV
requirement of 125 mrem. The plan will also be compared to an optimization goal of 10 mrem.
Through comparing the plan to the aforementioned dose limits, the plan should address the
minimizing of investigation false positives, reduce additional investigation costs while meeting
dose limit requirements.
4.1 Minimum Detectable Level
The Minimum Detectable Level (MDL) is the lowest amount of activity that can be
detected via bioassay by Test America, which is the laboratory that processes UNLV’s 24 hour
void urine bioassay samples. The MDL value reported by Test America, the independent
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laboratory that tests the bioassay samples, is 1.5 E-2 dpm or decays per minute (0.0002505 Bq)
and is determined from alpha spectrometry. For the project, it was important to convert the MDL
activity to a mass that could be used in conjunction with excretion curves provided by Oak Ridge
National Laboratory. Mass was calculated from the given activity with Eq. 7. The equation was
set equal to N, where A is the provided MDL value and λ can be calculated by Eq. 6. N was then
converted from the number of molecules to mass in the units, µg.
A = λN

(7)

Where:
A = Activity (Bq)
λ= Decay Constant
N = Number of molecules
The resulting MDL values for radionuclides uranium-238, uranium-235, and uranium-233 are in
Table 10.
Table 10: MDL values in µg for Uranium Radionuclides
Radionuclide

MDL (μg)

U-238

2.01 E-2

U-235

3.13 E-3

U-233

7.03 E-7

4.2 Determining Initial Dose from MDL
Once the mass was calculated, it was used to determine the initial inhaled mass to
calculate a dose at t = 90 days. It was assumed that the initial dose would be provided by an
acute inhalation dose. After inhalation, the uranium activity in urine decreases with time. If the
assumption that inhalation occurs immediately after the sampling period begins, the maximum
amount inhaled can be estimated from the ORNL excretion curves. The excretion curves [9] in
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the Oak Ridge National Laboratory papers provided values for the amount of uranium excreted
in urine per 24 hours (μg/24h) for Types F, M, and S. The excretion curves provided by Oak
Ridge National Laboratory were generated using ICRP 66’s Human Respiratory Tract Model and
ICRP 69’s biokinetic model for systemic uranium in adults [9]. To determine the initial dose a
setup like Ex. 1 was used; in this example all variables are provided, except for X which is
calculated via Eq.8. Once the X value, the initial mass calculated (µg), was determined it was
converted to N, the number of molecules, and was then used in Eq. 7 to determine the activity.
The activity in Bq was multiplied by a dose conversion factor to then compute the dose.
Example 1: Determining Dose
I1

X

M1

M2

X=

I1∗M2
M1

(8)

Where:
I1 = Initial mass at t = 0 on Oak Ridge National Laboratory excretion curves


I1 = 1 µg

M1 = Corresponding mass for time in question


provided by ORNL excretion curve and table

M2 = Mass calculated from MDL values (µg)
X = Calculated initial mass (µg)
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The dose conversion factor for calculations based off NRC regulations was calculated
from the Annual Limit Intake (ALI) values in NRC regulation 10CFR20, which are based on
ICRP 30 [8]. This is because federal regulations and UNLV regulations still utilize these older
values. These ALI values varied according to the radionuclide being used. To determine the dose
conversion factors in Sv/Bq, ALI values were converted to Bq and were divided into the annual
limit, 0.05 mSv. Conversely, doses based off newer regulations were calculated using the dose
conversion factors from ICRP 68 [6]. These values were in Sv/Bq and did not require any
manipulation to be used. Once the activity was multiplied by the dose conversion factor, it was
then converted from Sieverts (Sv) to millirem (mrem) because the UNLV quarterly investigation
limit is 125 mrem.
This process was used for each absorption type (F, M, and S) at days 30, 90, 180, and 360
for the radioisotopes of concern, uranium-238, uranium-235, and uranium-233. These days were
chosen because these are the options that correspond with the proposed bioassay schedule:
monthly (30 days), quarterly (90 days), semiannual (180 days), and annual (360 days). Also, it
was necessary to calculate the mass and resulting dose for uranium-233 because although it does
not occur naturally, it is still of major concern when monitoring individuals working with
uranium. If an individual at UNLV was working with uranium and received an exposure via
inhalation, there may be U-233 in their body that can be attributed to uranium samples used in
campus labs.
The information that results from the Alpha spectroscopy method employed by
TestAmerica for testing samples, provides one peak. The method is not able to distinguish
uranium-233 from uranium-234 and reports both isotopes in the same analysis and peak. Because
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the peak contains counts from both U-233 and U-234, the information calculated specific to
uranium-233 can be assumed to include uranium-234.
When calculating the initial mass, X value from Eq. 8, for absorption types F, M, and S
with the given MDL mass for uranium-238, the only value that changed from Eq. 8 was the
uranium amount (M1) provided by the excretion curves and tables because it varied with time;
For days 30 and 90 there was an explicit value provided in the table, however for days 180 and
360 a linear interpolation was used to determine the value [9]. For isotopes uranium-233 and
uranium-235, the initial mass, the half-life, MDL mass (M2), and dose conversion/ALI values
needed to be changed to reflect the respective isotope.
4.3 Calculating Dose
Once MDLs were calculated, it was necessary to determine if the current bioassay
program could meet the evaluation limit of 10 mrem and the investigation limit of 125 mrem
[12]. The doses were compared against the evaluation and investigation limits rather than the
annual limit of 5 rem. The doses were compared to the evaluation and investigation limits
because they were more in line with UNLV’s radiation safety program annual limit goal is 10%
of the 5 rem [15]. Comparing the calculated doses to the 10 mrem and 125 mrem allows for a
more proactive bioassay program, rather than reacting after the annual limit has already been
reached. Utilizing 10 mrem and 125 mrem as values for comparison, provides the radiation
safety program the flexibility of adding more precautionary measures to protect the worker. This
helps to avoid the automatic ejection of a worker from the laboratory because their annual limit
has been reached.
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Because uranium exists in nature, it can be assumed that individuals have natural levels
of uranium pre-existing in their body before working with uranium in a laboratory environment.
These levels are dependent upon the natural background levels of uranium that the individual has
been exposed to. In order to account for this natural background level, measurement uncertainty
and the natural variance of uranium in urine must be calculated to develop a bioassay program
that minimizes the need to investigate false positives. It is necessary to minimize false positives
to ensure any exposures not related to occupational procedures are not taken into account when
determining individuals’ annual occupational dose.
The concept used to calculate the initial mass resulting to the MDL was used. However,
to calculate the dose, the MDL mass value (M2) was replaced by the variance for each respective
group. The dose was then calculated for times 30 days, 90 days, 180 days, and 360 days for
chemical types F, M, and S. This calculation was repeated for radionuclides U-238, U-235, and
U-233.
Example 2: Determining Dose
I1

X

M1

M3

X=

I1∗M3
M1

(9)

Where:
I1 = Initial mass at t = 0 on Oak Ridge National Laboratory excretion curves


I1 = 1 µg
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M1 = Corresponding mass for time in question


provided by ORNL excretion curve and table

M3 = Variance estimate
X = Calculated initial mass (µg)
4.3.1 Estimating Variance in Bioassay Sampling
Variance estimates were based off urine concentration values provided by a Center for
Disease Control and Prevention (CDC) report on human exposure to environmental chemicals
[11]. The assumptions made from the document in calculating the variance was a confidence
interval of 95% and the information was taken from groups surveyed from 2001-2002 due to the
sample size being the largest during that year. The variance was calculated for the 50th percentile,
75th percentile, and 95th percentile groups for males and females in order to provide a wide scope
on how variance and dose were related to an individuals’ baseline. Eq. 10 was the equation used
to calculate variance for the 50th percentile, 75th percentile, and 95th percentile groups.
Data provided by the CDC was in the units of µg/L, which had to be converted to the
same units as the ORNL excretion curves (µg/24 hour void) in order to be used in calculations.
ICRP 23 provided the values for the volume of urine excreted per day (1400 mL/day for males
and 1000 mL/day for females) [5]. These ICRP 23 values allowed for the CDC data to be
converted and also allowed for the differences between males and females to be incorporated in
the calculations necessary to determine the min and max values in Eq. 10.

v=

max−min
2
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(10)

Where:
v = variance (μg/day)
max/min = values provided by CDC range of values


(dependent on percentile and gender)

The natural isotopic ratios in the uranium body burden must be taken into account in
order to find the baselines for each isotope. It is necessary to use the natural isotopic ratios
because uranium found in the general public is due to natural exposure to uranium. This was
done by taking the natural abundance percentage of each isotope and multiplying it by the
calculated variance for radionuclides U-238, U-235, and U-233. Since U-233 does not occur
naturally, the natural abundance for U-234 was used to find the baseline. It is important to note
that the information in the CDC report was provided in μg/L, so the values had to be converted to
μg/day to be consistent with the provided Oak Ridge National Laboratory excretion values
reported in μg/24 hrs.
The variance about the 0.05 μg and 0.5 μg action levels currently used by the UNLV
program is based on the range provided in ICRP 23 for the loss of uranium in urine for reference
man per day (0.05 μg – 0.5 μg) [5]. By using 0.05 μg and 0.5 μg, the variance is calculated for
the best and worst case scenario for individuals’ natural uranium body burden before working.
0.05 μg is representative of the individual who has the lowest amount of uranium in urine and 0.5
μg is representative of the maximum amount of uranium in urine. The CDC’s 95th percentile
values were used in Eq. 11 to calculate the variance for males and females for 0.05 μg and 0.05
μg. Because data from previous bioassays completed for UNLV were not available, the values
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from the 95th percentile were used because their range and mean were the closest in value to the
0.05 μg – 0.5 μg range provided by ICRP 23 values.

v=

max − min
median

(11)

Where:
v = Percent variance
max/min/median = values provided by CDC range of values


(dependent on percentile and gender)

As in the previous variance calculations it was necessary to convert the values to μg/day,
while also taking into account the volume of urine for each gender. The variance from Eq. 11
was multiplied by 0.05 μg and 0.5 μg and then natural abundance percentage for the uranium
radionuclide in question to determine the final variance for 0.05 μg and 0.5 μg.
For uranium-233, the natural abundance for uranium-234 was used in calculating the
variance. Again, this is due to uranium-233 not occurring naturally, but can enter the body via
occupational practices from working with U-233 and U-238 mixtures in UNLV laboratories.
Also, because the reported peak from the alpha spectroscopy done by TestAmerica combines
both uranium-233 and uranium-234, it is necessary to account for the isotope. Including the
variance in the dose calculations ensures that the dose calculated will minimize the investigation
of false positives. Also, the assumption is made that the dose calculated is the minimum dose
seen that does not have any environmental attributing factors; meaning any dose seen above that
level would be attributed to an occupational exposure.

43

4.4 Examination of the Current UNLV Bioassay Plan
The calculated measurement uncertainty above baseline doses for males and females in
the 50th percentile, 75th percentile, 95th percentile, 0.05 μg, and 0.5 μg at 90 days for
radionuclides uranium-238, uranium-235, and uranium-233 were evaluated to determine if the
current bioassay plan would meet the NRC and state annual limit of 5 rem. The doses (in mrem)
at 90 days were chosen for the comparison because the current bioassay schedule is based on a
quarterly schedule. The doses chosen for comparison were those that were calculated using the
dose conversion factors provided by NRC’s 10 CFR 20 due to the resulting doses being larger
than those doses calculated from ICRP 68’s conversion factors. This was assumed for a more
conservative approach when comparing doses to annual limits. Looking at Tables 11 and 12, it
was determined that for both males and females the 0.5 μg type S category in uranium-238 and
uranium-233 was not able to meet the 1.25 rem/quarter limit.
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U-233

U-235

U-238

Table 11: Dose Calculations (in mrem) at t = 90 days for Males
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

0.01471

0.03923

0.14712

0.22359

2.23586

Type M

0.03678

0.09808

0.36779

0.55896

5.58964

Type S

20.52828

54.74207

205.28276

311.97987

3119.7987

Type F

0.00068

0.00182

0.00681

0.01035

0.10350

Type M

0.00170

0.00454

0.01702

0.02588

0.25876

Type S

0.95030

2.53414

9.50302

14.44227

144.42274

Type F

0.02402

0.06406

0.24024

0.36511

3.65107

Type M

0.06864

0.18304

0.68640

1.04316

10.43162

Type S

33.52189

89.39173

335.21898
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509.45135 5094.51351

Table 12: Dose Calculations (in mrem) at t = 90 days for Females
50th
Percentile

U-238
U-235

95th
Percentile

0.05 μg

0.5 μg

0.01051

0.02102

0.11910

0.29048

2.90479

Type M 0.02627

0.05254

0.29774

0.72620

7.26199

Type F

U-233

75th
Percentile

Type S

14.66305

29.32611

166.18128

405.32020

4053.20

Type F

0.00049

0.00097

0.00551

0.01345

0.13447

Type M 0.00122

0.00243

0.01378

0.03362

0.33617

Type S

0.67879

1.35757

7.69292

18.76321

187.63215

Type F

0.01716

0.03432

0.19448

0.47434

4.74342

Type M 0.04903

0.09806

0.55566

1.35526

13.55263

47.88843

271.36775

661.87257

6618.72569

Type S

23.94421

4.5 UNLV Current Bioassay Schedule Meeting Investigation Limits
In Tables 11 and 12, the doses (mrem) at 90 days for each group were then compared to
the investigation limit to determine if the current bioassay schedule would be able to meet the
investigation limit. The investigation limit used was 125 mrem. The 125 mrem was determined
from dividing 500 mrem by 4 to represent the maximum dose a worker could be exposed to per
quarter and still meet the 500 mrem annual limit outlined by UNLV [15]. It can be determined
from Tables 11 and 12 that for both genders, uranium-238 and uranium-233 type S materials for
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groups 95th percentile, 0.05 μg, and 0.5 μg groups were not able to meet the investigation limit.
For uranium-235 type S materials, the 0.5 μg group was not able to meet the 125 mrem limit.
4.6 UNLV Current Bioassay Schedule Meeting Evaluation Limits
In Tables 11 and 12 the doses (mrem) at 90 days for each group were then compared to
the evaluation limit to determine if the current bioassay schedule would be able to meet the
evaluation limit. The evaluation limit used was 10 mrem. The 10 mrem was determined from the
500 mrem annual dose that was deemed by UNLV to be the target for the bioassay program [15].
500 mrem is 10% of the NRC/state annual dose of 5 rem, and 10 mrem is 2% of the target 500
mrem. The assumption of using 2% of 500 mrem was based on NRC Regulatory Guide 8.9
where the evaluation level for 5 rem was outlined to be 0.02 times the ALI, where the ALI is 5
rem [12].
Again, the doses used for the comparison were those calculated using dose conversion
factors that were calculated from the NRC 10 CFR 20 ALI values. The values in Tables 11 and
12 show for both males and females, most groups and chemical types were able to meet the goal
of 10 mrem. However, for type S in uranium-238 and uranium-233 in all percentiles/groups the
10 mrem was not met and for uranium-235 type S groups 0.05 μg and 0.5 μg the 10 mrem goal
was also not met. Type S material not meeting the goal of 10 mrem was predicted due to type S
materials being insoluble and resulting in larger doses than types F and M.
4.7 Optimizing Bioassay Program
It was determined which groups were able to meet the evaluation and investigation limits
could be met on a quarterly bioassay schedule. It was then important to determine if the bioassay
schedule frequency could be changed to optimize the bioassay program. ALARA requires for all
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reasonable actions to be taken and the current program may be over testing some groups, while
under testing others such as those individuals working with Class S materials. This can result in a
more financial burden related to the bioassay program. Studying how changing the bioassay
frequency allows for it to be determined if some individuals would be able to undergo less
frequent bioassays, while allowing those individuals who need bioassays more frequently than
what it currently being done to be protected also.
To determine bioassay frequency, doses were previously calculated per 30 days, 90 days,
180 days, and 360 days for males and females. These doses were then studied to determine the
latest at which a bioassay could be done while still being able to meet the evaluation and
investigation limit. Tables 13 - 16 show the frequency necessary for males and females to meet
the evaluation and investigation limit for radionuclide and absorption type. Males and females
were split to compare whether gender affected bioassay frequency. For a gender neutral bioassay
program, the more restrictive results would be used to base the program.
In Tables 13 and 14, groups that required a bioassay to be scheduled on a less than once
a month schedule, the specific length/number of days in between each bioassay was determined.
The process for determining the specific bioassay schedule included calculating the ratio of the
variance specific to the percentile to the calculated mass equal to the evaluation limit of 10
mrem. This ratio was calculated for each radionuclide and absorption type. The ratio was then
looked up on an excretion curve provided by the Oak Ridge National Laboratory paper [9] to see
what day corresponded to the mass. The asterisk (*) located next to some of the frequencies
denotes that to meet a specific limit, the bioassay frequency fell on the border between two
schedules. For these situations, a conservative approach was taken and the more frequent of the
schedules was chosen.
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U-233

U-235

U-238

Table 13: Bioassay Frequency to Meet 10 mrem (Males)
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

A

A

A

A

2X/YR

Type M

A

A

A

A

Q

Type S

< 1 day

< 1 day

< 1 day

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

Q

M

< 1 day

Type F

A

A

A

A

Q

Type M

A

A

A

A

M

Type S

< 1 day

< 1 day

< 1 day

< 1 day < 1 day

< 1 day < 1 day

U-238

Table 14: Bioassay Frequency to Meet 10 mrem (Females)
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

A

A

A

A

Q

Type M

A

A

A

A

Q

U-235

Type S

M

< 1 day

< 1 day

< 1 day

< 1 day

Type F

A

A

A

A

A

Type M

A

A

A

A

A

A

A

2X/YR

< 1 day*

< 1 day

Type F

A

A

A

A

Q*

Type M

A

A

A

A

M*

Type S

< 1 day

< 1 day

< 1 day

< 1 day

< 1 day

U-233

Type S
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Where for all tables:
A = Annual Bioassay
2X/YR = Semi-annual Bioassay
Q = Quarterly Bioassay
M = Monthly Bioassay
The same process was used in Tables 15 and 16 to determine the specific day for those
bioassay schedules less than a month, except the ratio took into account the mass equal to the
investigation limit of 125 mrem rather than 10 mrem. 125 mrem was evaluated to study whether
bioassay frequency for each group and radionuclide was affected if the dose limit was increased.
In Tables 15 and 16, the highlighted values for males and females depict bioassay frequency
changes for individuals working with a Type S material regardless of the percentile they
belonged to, as well as individuals in the 0.5 µg group overall.
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U-233

U-235

U-238

Table 15: Bioassay Frequency to Meet 125 mrem (Males)
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

M

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

A

A

M

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

2X/YR

< 1 day

< 1 day < 1 day

< 1 day < 1 day

U-233

U-235

U-238

Table 16: Bioassay Frequency to Meet 125 mrem (Females)
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

M

< 1 day

< 1 day

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

A

A

M

Type F

A

A

A

A

A

Type M

A

A

A

A

A

Type S

A

A

< 1 day

< 1 day

< 1 day
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4.8 Summary of Bioassay Plan Development
Based on the plans provided in Tables 13 - 16 that measured the feasibility of the current
quarterly bioassay schedule meeting the evaluation limit of 10 mrem and the investigation limit
of 125 mrem, the following plan suggests bioassay frequency that meets most working groups
that takes into account type of material and air monitoring. The doses used in structuring the plan
were the investigation limit dose of 125 mrem because they were more flexible and less
restrictive than the evaluation dose. The doses that were calculated were the minimum dose
above the baseline that would minimize the likelihood of a false positive reading. This was done
because it is a more realistic limit for the program to abide by as long as stringent air monitoring
is done in conjunction with the bioassay. It is important that the minimum dose above baseline
accounts for false positives because the false positives can result in unnecessary investigations.
Also, because uranium can be detected in urine at levels below the baseline average, the dose is
never truly zero even though the dose assigned is equal to zero. However, it is better to have
false positives rather than false negatives when investigating potential doses related to
occupational exposures.
The plan stated below uses air monitoring as a 1st line of defense for determining exposures,
while using a bioassay to support that exposures may or may not have occurred. Utilizing air
monitoring more aggressively is a preemptive measure that allows for the radiation protection
program at UNLV to be able to determine when and if there are exposures of concern that occur
before the current quarterly bioassay. Air monitoring allows for materials, such as Class Y or
insoluble materials, that cause higher internal dose when exposed and have long retention times
to be distinguished and proper precautions can be made to ensure the worker does not exceed
their annual limit. Frequent air monitoring is also beneficial for individuals who work with Class
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D or soluble materials, since they have short retention types and may void the body before the
quarterly bioassay that is currently in place. It also allows for a more tailored bioassay plan that
is based on an individuals’ baseline and material being worked with.
The bioassay plan below is designed to meet the goal of ensuring that exposures can be
detected below the investigational limit of 125 mrem values. The investigation limit was chosen
as the basis because it allows for flexibility in monitoring the program, unlike the evaluation
limit of 10 mrem. Although bioassay frequency standards for males and females were provided
for all type materials and uranium radionuclides of concern, it was determined that the bioassay
plan does not have to be gender based because there was not a significant difference in the
necessary frequency. With U-233, it was noted that a more conservative approach should be
taken for Type S materials. This precaution should especially be taken for females whose
baseline fall in the 75th percentile region. For the baselines, previous occupational exposure from
a different job can be included. Also, all workers are required to participate in the bioassay
program because it is a method of ensuring their safety; if a worker refuses to participate than
work will be suspended for said worker.
1. Conduct continuous air monitoring
A. Plan A: Continuous Air Monitors in laboratories, especially in those where Type Y
materials are being worked with.
B. Plan B: If continuous air monitoring is not available to support the work, continuous
air monitoring can be substituted. Samples are to be collected and counted within 21
days.
2. Individuals working with Type F and Type M material (Males and Females)
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A. All baselines and uranium radionuclides being used: Initial baseline taken before
work begins and an annual bioassay
3. Individuals working with Type S material (Males and Females):
A. U-238


Baseline in 50th and 75th Percentile: Annual Bioassay



Baseline in 95th Percentile: Monthly Bioassay



Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay must be done in conjunction with
continuous air monitoring

B. U-235


Individuals’ baseline in 50th and 95th Percentile: Annual Bioassay



Individuals’ baseline in 0.05 μg: Annual Bioassay



Baseline in 0.5 µg: Same as U-238

C. U-233


Individuals’ baseline in 50th: Semi-annual Bioassay



Individuals’ baseline in 95th Percentile: Monthly Bioassay must be done in
conjunction with continuous air monitoring
o Because performing daily bioassays are unrealistic, monthly bioassays can
be done in place of daily bioassays as long as continuous air monitoring is
done.



Baseline in 0.05 µg – 0.5 µg: Same as U-238

The condensed version of the proposed plan located in Appendix C, bases its goal off the
radiation exposure control limits outlined by UNLV at 0.5 rem, which is 10% of the annual limit
of 5 rem. This mean that the proposed plan would like to prevent workers from exceeding 125
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mrem on a quarterly basis, which is the current bioassay schedule. The proposed plan does meet
the goal of preventing workers from reaching the investigational limit of 125 mrem. Differences
from the current plan and the proposed plan include: bioassay frequency and taking into account
individual baselines. Because some baselines require an annual or semi-annual bioassay
frequency, some money may be saved in the respect of not conducting unnecessary quarterly
bioassays. For those individuals with a naturally higher baseline, this plan takes into account the
frequency necessary dependent upon the type of material being used. By utilizing frequency and
continuous air monitoring, the plan aims to save money in eliminating unnecessary
investigations.
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5.0 CONCLUSION
5.1 Discussion
The suggested bioassay program previously mentioned depends on air sampling and then
using a bioassay as a method of surveillance. In reading NRC Regulatory guide 8.9 and other
various university radiation protection programs, it was determined that the proposed bioassay
program uses air sampling as a 1st line of defense. Then proceeding to utilize bioassay as a means
of ensuring that air sampling is accurately monitoring and protecting workers. Air monitoring
also allows for a more proactive program that can determine when a potential dose has occurred,
rather than a reactive program that has to determine when a dose occurred months after it
happened.
The current UNLV program does not take into consideration a worker’s individual
baseline when determining bioassay frequency. Therefore, the suggested bioassay program
proposes that by tailoring a bioassay program to each worker there is the possibility for increased
safety for the worker. Also by making the program more tailored to the worker, it is possible to
conserve money. This is because it is not necessary to perform a quarterly bioassay on each
worker when type of radionuclide and absorption type is taken into consideration. If the
assumption is made that most workers will work with Type F and Type M materials, those
workers would only need an annual bioassay. This greatly decreases the cost for bioassays on the
majority; it also frees money to be spent on more frequent bioassays or other additional
measurements that would be necessary to protect the small percentage of individuals working
with Type S materials.
The ideal bioassay program would include vigilant use of air sampling and using
bioassays as investigational purposes. If it is not possible to depend on air sampling as an initial
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line of defense, then a bioassay program that is a hybrid of air sampling and scheduled bioassays
can be used as a substitute. The bioassay frequency that was initially suggested could be used to
determine which workers would require more monitoring. Those working with Type S material
would require additional air monitoring than what is already being done by the Radiation Safety
Office.
5.2 ICRP 30 Excretion Curve vs. Oak Ridge National Laboratory ICRP 66/69 curve
Although NRC 10 CFR 20 values are the basis for the current UNLV radiation safety
program, two cases were done to test which excretion curve will provide better values to base a
bioassay program. The uranium-238 radionuclide was chosen to base the excretion curve
because it accounts for 99.28% of uranium material. The Oak Ridge excretion curve is based off
the inhalation of 1 µg of uranium material. Because the experimental excretion curve based off
ICRP 30 takes initial activity (Bq) to determine dose, it was necessary to first determine the
activity equal to 1 µg of material. The resulting activity was used to create a new excretion curve
and activity at predetermined times. The experimental excretion curve was modeled for 10,000
days, which was the maximum number of days for the Oak Ridge National Laboratory excretion
curve.
The times that were chosen to compare the values of each curve was 30 days and 90 days.
This comparison was done to determine the accuracy of the ICRP 30 excretion curves, as well as
to see which curve provided the most conservative approach in determining bioassay frequency.
The initial inhalation for the ICRP 30 curve was 1 µg because that is what was used as the Oak
Ridge National Laboratory Excretion curve’s initial inhalation mass. Once the activity was
determined at the aforementioned times, the activity was converted to mass (µg) for comparison
to the Oak Ridge National Laboratory excretion curves. Tables 17-19 show the comparison of
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mass of uranium excreted in a 24 hour void between the ICRP 30 experimental excretion curve
and the Oak Ridge excretion curve.
Table 17: Mass of uranium in a 24 hour void (Class D Material)
Time
(days)
30
90

Activity
(Bq)
5.5205E-9
5.754E-10

ICRP 30 Mass
(µg)
4.43E-7
4.624E-8

Oak Ridge Mass
(µg)
6.6E-4
1.2E-4

Table 18: Mass of uranium in a 24 hour void (Class W Material)
Time
(days)
30
90

Activity
(Bq)
1.8727E-9
1.8711E-9

ICRP 30 Mass
(µg)
1.505E-7
1.503E-7

Oak Ridge Mass
(µg)
2.6E-4
1.2E-4

Table 19: Mass of uranium in a 24 hour void (Class Y Material)
Time
(days)
30
90

Activity
(Bq)
3.0859E-10
2.5808E-10

ICRP 30 Mass
(µg)
2.48E-8
2.07E-8

Oak Ridge Mass
(µg)
7.6E-6
4.3E-6

Based on the values in the table, the Oak Ridge National Laboratory excretion curves
provide the more realistic, but less conservative estimation for the amount of mass that can be
excreted. These curves are more realistic because the data to create the excretion curves are more
updated in taking into account how the body functions and deals with radioactive material. This
amount can then be converted into a useable dose that can be used to determine an initial
inhalation dose. The values determined in Tables 17-19 are based on ICRP 66, 69, and 100
which contain more updated values than those provided in ICRP 30. Since current federal and
state regulations are based on ICRP 30 values, it is suggested that consideration be taken into
utilizing these values when assigning a more conservative dose.
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In addition to utilizing ICRP 30 values for assigning more conservative doses, it is
important to include individual baselines when determining dose for workers. Baselines for the
initial uranium concentration is an important aspect of uranium internal dosimetry. Baselines
allow for radiation safety programs to monitor and study fluctuations in an individual’s exposure.
It also allows for the radiation safety program to determine what range of uranium found in a
bioassay is considered to be normal or should be of concern. Although the current bioassay
program uses the baseline values when they are made available, it is important that the bioassay
frequency reflects the initial baseline. Including the initial baselines would allow for a more
tailored approach in protecting workers to help ensure there are less false positives detected
during bioassays, rather than taking a blanket approach with scheduling bioassay frequency. The
baselines needed for the bioassay frequency would be determined from the initial bioassay done
on each worker before they begin working with any material.
5.3 Future Work
This work focused primarily protecting those who perform on uranium work at UNLV.
For future work, it is important that existing bioassay data be made readily available for use in
determining bioassay frequencies. The existing bioassay data would be pertinent in establishing
more realistic variance values specific to UNLV workers for the bioassay samples, rather than
having to utilize values general data from the CDC paper. Potential future work that can be done
to further increase protection could be considering fecal sample analysis in addition to current
bioassay measurements. Although fecal sampling is not the most appealing method of bioassay,
it can provide more accurate measurements to determine dose from exposures.
Research can also be expounded by developing an excretion curve based on the ICRP 66
Human Respiratory Tract Model. This project focused on creating an excretion curve based on
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ICRP 30. The excretion curve based on ICRP 66’s Human Respiratory Tract Model would also
include the ICRP 100 Human Alimentary Tract and the updated uranium biokinetic model in
ICRP 69. These are the models that provide the basis for the Oak Ridge excretion curves. It
would allow for a method of verifying that the excretion curve was created accurately, which
was not possible for the ICRP 30 model. It would also provide UNLV with the ability to create
their own updated excretion curves that can vary depending on the amount of inhaled activity.
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APPENDIX A: Excretion Curves Created in MATLAB

Figure 12: Class W Material Excretion Curve (No Direct Impulse)
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Figure 13: Class W Material Excretion Curve (Including Direct Impulse)
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Figure 14: Class Y Material Excretion Curve (No Direct Impulse)
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Figure 14: Class Y Material Excretion Curve (Including Direct Impulse)
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APPENDIX B: Dose Calculations

U-233

U-235

U-238

Table 20: Dose Calculations (in mrem) at t = 30 days for Males
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

2.67E-3

7.13E-3

2.67E-2

4.07E-2

4.07E-1

Type M

1.70E-2

4.53E-2

1.70E-1

2.58E-1

2.58

Type S

1.16E+1

3.10E+1

1.16E+2

1.77E+2

1.77E+3

Type F

1.24E-4

3.30E-4

1.24E-3

1.88E-3

1.88E-2

Type M

7.86E-4

2.10E-3

7.86E-3

1.19E-2

1.19E-1

Type S

5.38E-1

1.43

5.38

8.17

8.17E+1

Type F

4.37E-3

1.16E-2

4.37E-2

6.64E-2

6.64E-1

Type M

3.17E-2

8.45E-2

3.17E-1

4.81E-1

4.81

Type S

1.9E+1

5.06E+1

1.9E+2

2.88E+2

2.88E+3
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U-233

U-235

U-238

Table 21: Dose Calculations (in mrem) at t = 30 days for Females
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

1.91E-3

3.28E-3

3.17E-2

5.28E-2

5.28E-1

Type M

1.21E-2

2.43E-2

1.37E-1

3.35E-1

3.35

Type S

8.30

1.66E+1

9.40E+1

2.29E+2

2.29E+3

Type F

8.84E-5

1.77E-4

1.00E-3

2.44E-3

2.44E-2

Type M

5.61E-4

1.12E-3

6.36E-3

1.55E-2

1.55E-1

Type S

3.84E-1

7.68E-1

4.35

1.06E+1

1.06E+2

Type F

3.12E-3

6.24E-3

3.54E-2

8.62E-2

8.62E-1

Type M

2.26E-2

4.53E-2

2.56E-1

6.26E-1

6.26

Type S

1.35E+1

2.71E+1

1.54E+2

3.74E+2

3.74E+3
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U-233

U-235

U-238

Table 22: Dose Calculations (in mrem) at t = 180 days for Males
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

5.38E-2

1.44E-1

5.38E-1

8.18E-1

8.18

Type M

6.71E-2

1.79E-1

6.71E-1

1.02

1.02E+1

Type S

2.66E+1

7.09E+1

2.66E+2

4.04E+2

4.04E+3

Type F

2.49E-3

6.64E-3

2.49E-2

3.79E-2

3.79E-1

Type M

3.11E-3

8.28E-3

3.11E-2

4.72E-2

4.72E-1

Type S

1.23

3.28

1.23E+1

1.87E+1

1.87E+2

Type F

8.79E-2

2.34E-1

8.79E-1

1.34

1.34E+1

Type M

1.25E-1

3.34E-1

1.25

1.9

1.9E+1

Type S

4.34E+1

1.16E+2

4.34E+2

6.6E+2

6.6E+3
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Table 23: Dose Calculations (in mrem) at t = 180 days for Females
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

3.84E-2

7.69E-2

4.36E-1

1.06

1.06E+1

Type M

4.79E-2

9.58E-2

5.43E-1

1.32

1.32E+1

Type S

1.9E+1

3.8E+1

2.15E+2

5.25E+2

5.25E+3

Type F

1.78E-3

3.56E-3

2.02E-2

4.92E-2

4.92E-1

Type M

2.22E-3

4.44E-3

2.51E-2

6.13E-2

6.13E-1

Type S

8.79E-1

1.76

9.96

2.43E+1

2.43E+2

Type F

6.28E-2

1.26E-1

7.12E-1

1.74

1.74E+1

Type M

8.94E-2

1.79E-1

1.01

2.47

2.47E+1

Type S

3.10E+1

6.2E+1

3.51E+2

8.57E+2

8.57E+3
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Table 24: Dose Calculations (in mrem) at t = 360 days for Males
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

2.81E-1

7.49E-1

2.81

4.27

4.27E+1

Type M

1.87E-1

4.99E-1

1.87

2.84

2.84E+1

Type S

3.29E+1

8.78E+1

3.29E+2

5.01E+2

5.01E+3

Type F

1.3E-2

3.47E-2

1.30E-1

1.98E-1

1.98

Type M

8.66E-3

2.31E-2

8.66E-2

1.32E-1

1.32

Type S

1.52

4.07

1.25E+1

2.32E+1

2.32E+2

Type F

4.59E-1

1.22

4.59

6.98

6.98E+1

Type M

3.49E-1

9.31E-1

3.49

5.30

5.30E+1

Type S

5.38E+1

1.43E+2

5.38E+2

8.17E+2

8.17E+3
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Table 25: Dose Calculations (in mrem) at t = 360 days for Females
50th
Percentile

75th
Percentile

95th
Percentile

0.05 μg

0.5 μg

Type F

2.01E-1

4.02E-1

2.28

5.55

5.55E+1

Type M

1.34E-1

2.67E-1

1.51

3.69

3.69E+1

Type S

2.35E+1

4.71E+1

2.67E+2

6.5E+2

6.5E+3

Type F

9.29E-3

1.86E-2

1.05E-1

2.57E-1

2.57

Type M

6.18E-3

1.24E-2

7.01E-2

1.71E-1

1.71

Type S

1.09

2.18

1.23E+1

3.01E+1

3.01E+2

Type F

3.28E-1

6.56E-1

3.72

9.06

9.06E+1

Type M

2.49E-1

4.99E-1

2.83

6.89

6.89E+1

Type S

3.84E+1

7.68E+1

4.35E+2

1.06E+3

1.06E+4
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APPENDIX C: UNLV Proposed Bioassay Plan

TYPE OF
MATERIAL

ACTION

F
Initial Baseline
M

Annual Bioassay

S

U-238
Baseline in 50th-75th Percentile: Annual Bioassay
Baseline in 95th Percentile: Monthly Bioassay
Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay with CAM
U-235
Baseline in 50th-95th Percentile: Annual Bioassay
Baseline in 0.05 µg: Annual Bioassay
Baseline in 0.5 µg: Monthly Bioassay with CAM
U-233
Baseline in 50th Percentile: Annual Bioassay
Baseline in 75th Percentile: Semiannual Bioassay
Baseline in 95th Percentile: Monthly Bioassay with CAM (instead
of Daily)
Baseline in 0.05 µg – 0.5 µg: Monthly Bioassay with CAM
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